Business Wire

ADVA

8.12.2022 09:01:35 CET | Business Wire | Press release

Share
ADVA’s new OSA 3350 SePRC™ optical cesium clock breaks records with industry’s longest holdover

ADVA (FSE: ADV) today launched its latest optical cesium atomic clock solution, providing unprecedented protection for critical network infrastructure systems that rely on synchronization from GNSS. The new OSA 3350 Super ePRC (SePRC) delivers extensive timing holdover with high-performance stability and lifetime that significantly outperforms any other solution on the market. It offers a vital lifeline to time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS) providers, defense organizations, communication network operators, power utilities and transportation network operators looking to mitigate the risk of jamming and spoofing attacks. As a GBaaS solution, the OSA 3350 SePRC™ provides a backup to satellite-based synchronization, helping prevent severe harm to businesses and society that long GNSS outages can cause. The new device will enable the most robust PNT solution on the market.

“Across all nations, our well-being and safety are more dependent than ever on critical networks using satellite-derived synchronization. At the same time, this infrastructure has never been more exposed to risk. Mitigating this risk is a fundamental part of a PNT framework. That’s why we’ve created a solution that offers a new level of protection by holding accurate timing for far longer than any other available technology,” said Gil Biran, GM of Oscilloquartz, ADVA. “With the industry-leading holdover of our Oscilloquartz OSA 3350 SePRC, operators can ensure that even when timing networks come under sustained GNSS cyberattack, the essential services we all depend on will continue to function.”

The Oscilloquartz OSA 3350 SePRC is a super ePRC that leverages optical pumping technology to deliver full high-performance frequency stability. When used with enhanced primary reference time clocks (ePRTCs), it delivers holdover of 100 nanoseconds for a minimum of 45 days and typically 55 days. In order to achieve the same performance with the market’s current solutions, users would need multiple magnetic cesium clocks. The OSA 3350 SePRC provides optimum stability for ten years, a substantially longer lifespan compared with all other high-performance magnetic cesium clocks. Featuring a fully modular design, the all-digital solution carries a wide range of synchronization output interfaces and supports modern and secured management capabilities with SNMP. What’s more, the holdover performance of the OSA 3350 ePRC+ has also been enhanced. Launched in 2020 as the market’s first high-performance optical cesium clock, it now supports 100nsec accuracy over a minimum period of 25 days and typically 30 days.

“The current geopolitical situation makes protecting mission-critical timing networks a matter of national security and fundamental to PNT solutions. Rogue states with vast resources pose a significant threat, but so too do individuals who can commit cyberattacks on GNSS-derived timing using inexpensive off-the-shelf devices. That’s why the launch of our unparalleled PNT solution is so crucial. Our OSA 3350 SePRC provides the most reliable, stable, robust and long-lasting backup for when GNSS is compromised or otherwise unavailable,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, ADVA. “And as well as outstanding holdover, our new solution is also simple and easy to use with full integration into our Ensemble management software suite.”

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005679/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye